Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

July 1, 2021
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 1 July 2021, 07:00 am CEST   Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpoints[i] Over 90% reduction in mean frequency of therapeutic paracentesis versus baseline All patients experienced at least 50% reduction in mean frequency of therapeutic paracentesis per...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES